Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698240 | 0.85 | GABRA1 (0.49) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL501378 | 0.85 | MRGPRX4 (0.41) | ENPP2BACE1 | |
| SCHEMBL3168839 | 0.83 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL11942311 | 0.83 | IDO1 (0.38) | CYP3A4 | |
| SCHEMBL5871245 | 0.82 | CYP4F2 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL22198892 | 0.82 | BACE1 (0.35) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL722684 | 0.81 | IDO1 (0.56) | TAAR1 | |
| SCHEMBL21367138 | 0.81 | CYP3A4 (0.56) | ENPP2TAAR1CYP3A4PKMKDM4E | |
| SCHEMBL631424 | 0.81 | MAOB (0.42) | CYP3A4ACHE | |
| SCHEMBL15687564 | 0.81 | IDO1 (0.36) | CYP3A4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025001407-A1 | POLYARYL-CONTAINING MACROCYCLIC COMPOUNDS AND USES THEREOF | 浙江养生堂天然药物研究所有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-119192199-A | Polyaryl-containing macrocyclic compounds and uses thereof | 浙江养生堂天然药物研究所有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024199069-A1 | POLYARYL-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118724916-A | Polyaryl-containing macrocyclic compounds and uses thereof | 浙江养生堂天然药物研究所有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| CN-109526220-B | Tetrahydropyrimidine and tetrahydropyridino-diazepine compounds for use in the treatment of pain and pain related conditions | 埃斯特维制药股份公司 | 2021-12-21 | — | — | CN | disclosed |
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3843742-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-07-07 | — | — | EP | disclosed |
| CN-112638389-A | CD73 inhibitors and therapeutic uses thereof | 江苏恒瑞医药股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| US-10590140-B2 | Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| EP-2176223-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009007015-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | WO | disclosed |
| US-7199154-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST COMPANY (CA) | 2007-04-03 | — | — | US | disclosed |
| US-7199154-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST COMPANY (CA) | 2007-04-03 | — | — | US | disclosed |
| US-20050261245-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST COMPANY (CA) | 2005-11-24 | — | — | US | disclosed |
| EP-1527045-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011421-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-02-05 | — | — | WO | disclosed |
| US-6538033-B2 | E.g., 1, 3-(nitrooxymethyl)phenyl 2-hydroxybenzoate; treatomg coronary artery disease. | HUNTINGTON MEDICAL RESEARCH INSTITUTES | 2003-03-25 | — | — | US | disclosed |
| US-20020032232-A1 | Nitric oxide donor compounds | NICOX, S.A. (FR) | 2002-03-14 | — | — | US | disclosed |
| EP-0485026-A2 | Antimanic phenoxymethylene bisphosphonate derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | ENTPD5, ENTPD1, NT5E | GABRA1 3320/4885GABRG2 3065/4885GABRB3 2706/4885 |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | ENTPD5, ENTPD1, NT5E | GABRA1 3320/4885GABRG2 3065/4885GABRB3 2706/4885 |
| US-10590140-B2 | Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions | CACNA1G, CACNA1B, CACNA1D | GABRA1 163/4885GABRG2 206/4885GABRB3 136/4885 |
| US-20050261245-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | PTGIS, PTGS1, PTGS2 | GABRA1 3756/4885GABRG2 2797/4885GABRB3 3568/4885 |
| US-20020032232-A1 | Nitric oxide donor compounds | NOS1, NOS3, NOS2 | GABRA1 1553/4885GABRG2 2420/4885GABRB3 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.